HighTower Advisors’s AbbVie ABBV Stock Holding History

HighTower Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-34,500	Closed	-$128K	–	3668
2024 Q1	$128K	Buy	+34,500	New	+$5.95M	﹤0.01%	3096
2022 Q2	–	Sell	-16	Closed	-$21K	–	3219
2022 Q1	$21K	Buy	+16	New	+$2.32K	﹤0.01%	3159
2019 Q3	–	Sell	-200	Closed	-$2K	–	2404
2019 Q2	$2K	Buy	+200	New	+$15.7K	﹤0.01%	2344

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HighTower Advisors's ABBV Position: Q1 2026 in Review

HighTower Advisors increased its AbbVie (ABBV) stake by 1.8% in Q1 2026, buying an estimated $6.46M and bringing the position to 1,658,024 shares worth $361M. The position accounts for 0.38% of the portfolio, ranked #46.

HighTower Advisors first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $380M in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

HighTower Advisors held 1,658,024 shares of AbbVie worth $361M as of Q1 2026.
HighTower Advisors bought 29,113 AbbVie shares in Q1 2026, an estimated $6.46M.
AbbVie made up 0.38% of HighTower Advisors's portfolio in Q1 2026, its #46 holding.
HighTower Advisors first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
HighTower Advisors's AbbVie position peaked at $380M in Q3 2025.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.